Equities analysts forecast that NxStage Medical, Inc. (NASDAQ:NXTM) will post earnings per share (EPS) of ($0.03) for the current fiscal quarter, Zacks Investment Research reports. Three analysts have provided estimates for NxStage Medical’s earnings. The lowest EPS estimate is ($0.05) and the highest is $0.00. NxStage Medical also reported earnings per share of ($0.03) in the same quarter last year. The company is expected to issue its next earnings results before the market opens on Wednesday, August 9th.

On average, analysts expect that NxStage Medical will report full-year earnings of ($0.04) per share for the current financial year, with EPS estimates ranging from ($0.12) to $0.01. For the next year, analysts anticipate that the firm will post earnings of $0.11 per share, with EPS estimates ranging from $0.06 to $0.17. Zacks’ earnings per share calculations are a mean average based on a survey of research firms that that provide coverage for NxStage Medical.

NxStage Medical (NASDAQ:NXTM) last issued its quarterly earnings data on Tuesday, May 9th. The medical device company reported ($0.02) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.03) by $0.01. NxStage Medical had a negative net margin of 1.25% and a negative return on equity of 2.31%. The firm had revenue of $96.83 million during the quarter, compared to analysts’ expectations of $95.31 million. During the same period last year, the company earned ($0.02) earnings per share. The business’s revenue was up 8.5% on a year-over-year basis.

A number of analysts have recently weighed in on NXTM shares. BTIG Research reaffirmed a “buy” rating and issued a $27.00 target price on shares of NxStage Medical in a research report on Wednesday, May 10th. Jefferies Group LLC cut their price objective on shares of NxStage Medical from $38.00 to $33.00 and set a “buy” rating on the stock in a research report on Wednesday, May 10th. Canaccord Genuity reissued a “buy” rating and set a $32.00 price objective on shares of NxStage Medical in a research report on Monday, May 8th. Northland Securities downgraded shares of NxStage Medical from an “outperform” rating to a “market perform” rating in a research report on Thursday, May 4th. Finally, BidaskClub raised shares of NxStage Medical from a “hold” rating to a “buy” rating in a report on Friday, June 30th. Three investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average price target of $30.50.

NxStage Medical (NASDAQ NXTM) opened at 24.29 on Thursday. The company’s market capitalization is $1.60 billion. NxStage Medical has a 52-week low of $20.45 and a 52-week high of $30.80. The company’s 50 day moving average is $24.03 and its 200-day moving average is $25.95.

In other news, SVP Winifred L. Swan sold 3,500 shares of NxStage Medical stock in a transaction that occurred on Monday, May 15th. The shares were sold at an average price of $21.94, for a total transaction of $76,790.00. Following the sale, the senior vice president now owns 17,770 shares in the company, valued at $389,873.80. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, President Joseph E. Turk, Jr. sold 1,000 shares of NxStage Medical stock in a transaction that occurred on Wednesday, May 3rd. The shares were sold at an average price of $29.95, for a total transaction of $29,950.00. Following the sale, the president now owns 77,903 shares in the company, valued at approximately $2,333,194.85. The disclosure for this sale can be found here. Insiders sold a total of 23,150 shares of company stock worth $538,441 in the last quarter. Company insiders own 4.70% of the company’s stock.

Several large investors have recently added to or reduced their stakes in NXTM. SG Americas Securities LLC acquired a new position in NxStage Medical during the first quarter worth $140,000. Ameritas Investment Partners Inc. acquired a new position in NxStage Medical during the first quarter worth $148,000. Menta Capital LLC acquired a new position in NxStage Medical during the first quarter worth $212,000. Jane Street Group LLC acquired a new position in NxStage Medical during the first quarter worth $213,000. Finally, PEAK6 Investments L.P. acquired a new position in NxStage Medical during the first quarter worth $214,000. Hedge funds and other institutional investors own 95.43% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: This piece was first reported by American Banking News and is the property of of American Banking News. If you are viewing this piece on another publication, it was stolen and reposted in violation of U.S. and international copyright legislation. The correct version of this piece can be viewed at https://www.americanbankingnews.com/2017/07/27/analysts-expect-nxstage-medical-inc-nxtm-will-post-earnings-of-0-03-per-share.html.

About NxStage Medical

NxStage Medical, Inc is a medical technology company. The Company develops, manufactures and markets products and services for patients suffering from chronic or acute kidney failure. It operates through three segments. The System One segment includes revenues from the sale and rental of the System One and PureFlow SL dialysate preparation equipment and the sale of disposable products in the home and critical care markets.

Get a free copy of the Zacks research report on NxStage Medical (NXTM)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for NxStage Medical (NASDAQ:NXTM)

Receive News & Ratings for NxStage Medical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NxStage Medical Inc. and related companies with MarketBeat.com's FREE daily email newsletter.